The US Renal Disease Market forecast projects a period of significant expansion, driven by the increasing burden of chronic kidney disease and the continuous evolution of treatment modalities. The forecast anticipates that the prevalence of CKD will continue to rise, fueled by the epidemics of diabetes and obesity in the US. This will create a larger patient population requiring early-stage management as well as late-stage interventions like dialysis and transplantation. The forecast also predicts that the dialysis segment, which is the largest component of the market, will see a shift in preferences. While in-center hemodialysis will remain a dominant modality, home-based therapies such as peritoneal dialysis and home hemodialysis are expected to grow at a faster rate. This trend is driven by patient preference for greater autonomy and quality of life, as well as a growing recognition among providers of the potential cost savings and improved health outcomes associated with home-based care.

The forecast also considers the impact of technological advancements. The development of more portable and user-friendly home dialysis machines, as well as innovations in wearable kidney devices and regenerative medicine, could reshape the market in the long term. These technologies, while still in the early stages, have the potential to disrupt traditional care models and provide more effective and convenient solutions for patients. Furthermore, the forecast accounts for the increasing focus on preventive care and early diagnosis, which could, in the long run, slow the progression of CKD and shift the market's emphasis from late-stage treatment to early-stage management. The overall outlook for the US renal disease market is one of sustained growth, with a clear trend towards more patient-centric and technologically advanced care.